joined the UMKC School of Pharmacy Division of Pharmacology in 1987. He
is the current coordinator of the Dental Pharmacology Course (Pharm
507), and Basic Toxicology course (Pharm 463/509). He is the recipient
of the 2005-2006 UMKC chapter of Rho Chi “Outstanding Instructor of the
Year”. Dr. Badr is a member of the Editorial Board of the Journal
of Carcinogenesis, and the Editor-in-Chief of PPAR
Research, an international journal devoted to
publications on the “Peroxisome Proliferator-Activated Receptors” (PPARs),
proteins which are implicated in numerous conditions and diseases such
as aging, cancer, diabetes, obesity, inflammation, immunity, and
(Pharmacy) Cairo University, Egypt, 1973
M.S. (Pharmaceutical Chemistry), Cairo University, Egypt, 1978
Ph.D. (Pharmacology/Toxicology), University of Louisville, 1983
Postdoctoral Fellow, University of North Carolina-Chapel Hill, 1984-1987
focus of research activities in Dr. Badr’s laboratory is on the
investigation of molecular and biochemical mechanisms whereby various
therapeutic agents and industrial chemicals cause non-genotoxic liver
cancer, as well as modulate immunity and inflammatory responses. Roles
of aging, metabolic diseases (diabetes) and nutrients in these processes
are characterized using biochemical and molecular biological techniques.
(2006). Inhibition of carrageenan-induced cutaneous
inflammation by PPAR agonists is dependent on hepatocyte-specific
retinoid X receptor alpha
Res. (in press).
Kriedt, C., Nagalingam, S., and M. Badr (2005).
Central administration of perfluorooctanoic acid inhibits
cutaneous inflammation. Inflamm. Res. 54, 235-242.
Youssef, J., and M. Badr (2005). Aging
and enhanced hepatocarcinogenicity by peroxisome
proliferator-activated receptor alpha agonists. Aging
Research Reviews 4, 103-118.
Badr, M., and Birnbaum, L (2004). Enhanced Potential for Oxidative
Stress in Livers of Senescent Rats by the peroxisome
Proliferator-Activated receptor alpha Agonist
perfluorooctanoic Acid. Mech. Ageing & Develop. 125,
J., and M. Badr (2004). Role of peroxisome
proliferator-activated receptors in inflammation control. J.
Biomed Biotech. 2004, 156-166.
(2004). Peroxisome proliferator-activated receptor alpha
and cancer: friends or foes?. Int. J. Cancer Prevention 1,
C., Youssef, J., Cunningham, M.L., and M. Badr
(2004). Correlation between thyroid hormone status and
hepatic hyperplasia and hypertrophy caused by the peroxisome
proliferator-activated receptor alpha agonist
Wy-14,643. J. Carcinogenesis 3, 9.